Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMAVERA study of early C.E.R.A. treatment in CKD stage III
2009-015114-22Phase 2Completed
- Sponsor
- Roche
- Start
- May 2010
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of methoxy polyethylene glycol-epoetin beta in chronic kidney disease (CKD) (2 arms), sponsored by Roche. Primary endpoint: Change in estimated glomerular filtration rate over time. Started May 2010; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2009-015114-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015114-22.